NO991906L - Sirkulµrpermutert erythropoietin reseptoragonister - Google Patents

Sirkulµrpermutert erythropoietin reseptoragonister

Info

Publication number
NO991906L
NO991906L NO991906A NO991906A NO991906L NO 991906 L NO991906 L NO 991906L NO 991906 A NO991906 A NO 991906A NO 991906 A NO991906 A NO 991906A NO 991906 L NO991906 L NO 991906L
Authority
NO
Norway
Prior art keywords
permeated
circulated
receptor agonists
erythropoietin receptor
erythropoietin
Prior art date
Application number
NO991906A
Other languages
English (en)
Norwegian (no)
Other versions
NO991906D0 (no
Inventor
Charles A Mcwherter
Yiqing Feng
Neena Summers
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO991906D0 publication Critical patent/NO991906D0/no
Publication of NO991906L publication Critical patent/NO991906L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO991906A 1996-10-25 1999-04-21 Sirkulµrpermutert erythropoietin reseptoragonister NO991906L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3404496P 1996-10-25 1996-10-25
PCT/US1997/018703 WO1998018926A1 (en) 1996-10-25 1997-10-23 Circularly permuted erythropoietin receptor agonists

Publications (2)

Publication Number Publication Date
NO991906D0 NO991906D0 (no) 1999-04-21
NO991906L true NO991906L (no) 1999-04-21

Family

ID=21873960

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991906A NO991906L (no) 1996-10-25 1999-04-21 Sirkulµrpermutert erythropoietin reseptoragonister

Country Status (13)

Country Link
US (1) US20060172932A1 (pl)
EP (1) EP0939816A1 (pl)
JP (1) JP2001503266A (pl)
KR (1) KR20000052807A (pl)
CN (1) CN1234073A (pl)
AU (1) AU721196B2 (pl)
BR (1) BR9712675A (pl)
CA (1) CA2268001A1 (pl)
CZ (1) CZ130199A3 (pl)
NO (1) NO991906L (pl)
NZ (1) NZ334546A (pl)
PL (1) PL189756B1 (pl)
WO (1) WO1998018926A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP4480398B2 (ja) 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
KR101183770B1 (ko) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. Ｅ1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
EP1966237A2 (en) * 2005-11-24 2008-09-10 Laboratoires Serono SA Erythropoietin polypeptides and uses thereof
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
DK2859015T3 (en) 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
CN110144010B9 (zh) 2018-02-14 2021-01-05 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH05502463A (ja) * 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン ハイブリツド成長因子
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Also Published As

Publication number Publication date
BR9712675A (pt) 1999-10-19
NZ334546A (en) 2000-12-22
NO991906D0 (no) 1999-04-21
AU721196B2 (en) 2000-06-29
US20060172932A1 (en) 2006-08-03
AU5081098A (en) 1998-05-22
WO1998018926A1 (en) 1998-05-07
JP2001503266A (ja) 2001-03-13
PL332960A1 (en) 1999-10-25
CN1234073A (zh) 1999-11-03
KR20000052807A (ko) 2000-08-25
EP0939816A1 (en) 1999-09-08
CZ130199A3 (cs) 1999-07-14
CA2268001A1 (en) 1998-05-07
PL189756B1 (pl) 2005-09-30

Similar Documents

Publication Publication Date Title
NO991906D0 (no) Sirkulµrpermutert erythropoietin reseptoragonister
ATA78596A (de) Rotationsviskosimeter
EP0984779A4 (en) SOMATOSTATIN AGONISTS
DE69724663D1 (de) Abstandshalter
ATE215369T1 (de) Carbazolanaloge als selektive beta3-adrenergische agonisten
DE69718508D1 (de) Antitraspirant zusammensetzung
DE59711530D1 (de) Färbemittel
ATE222083T1 (de) Fixierende, glanzgebende kosmetische zusammensetzung
ID18359A (id) Komposisi mikrokapsul
ID19589A (id) Komposisi
DK0810025T3 (da) Homogeniseringsventil
NL1006126A1 (nl) Houder.
BR9707835A (pt) Composiç
FI971633A7 (fi) Puristinjärjestelmä
DE59708449D1 (de) Substituierte p-trifluormethylphenyluracile
DE59707428D1 (de) Substituierte 1-methyl-3-benzyluracile
BR9709815A (pt) Composicão
DE59711889D1 (de) Substituierte pyrazol-3-ylbenzazole
DE19782032T1 (de) Konzepthalter
DE69707199D1 (de) Dokumentenhalter
DE59708674D1 (de) Substituierte 3-phenylpyrazole
DE59712222D1 (de) Substituierte phenyluracile
DE59711493D1 (de) Polymerzusammensetzung
ATA86496A (de) Rotationsviskosimeter
FI963935A7 (fi) Polymeerikoostumus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application